Neurology News and Research

Latest Neurology News and Research

ABMS awarded HHS contract to align meaningful use of HIT, ABMS MOC program

The American Board of Medical Specialties announced today a contract from the U.S. Department of Health and Human Services to align the meaningful use of health information technology and the ABMS Maintenance of Certification program, which was created by ABMS and its 24 Member Boards to promote lifelong learning and self assessment for physician specialists. The contract was awarded by the HHS Office of the National Coordinator for HIT.

8 Oct 2010

IMNG relaunches websites for Internal Medicine News, Hospitalist News

International Medical News Group, an Elsevier company that provides medical news to physicians, today announced the relaunch of its websites for Internal Medicine News (www.internalmedicinenews.com) and Hospitalist News.

8 Oct 2010

Study finds boosting mitochondria may delay onset of Parkinson's disease

In a study that sheds new light on the causes of Parkinson's disease, researchers report that brain cells in Parkinson's patients abandon their energy-producing machinery, the mitochondria. A shutdown in fuel can have devastating effects on brain cells, which consume roughly 20 percent of the body's energy despite making up only 2 percent of body weight.

8 Oct 2010

Parkinson’s disease pathology breakthrough

Researchers have found that brain cells of people with early Parkinson's disease have damaged powerhouses. In a new study they have identified 10 groups of gene sets related to the energy production problems in the brain cells of these people.

8 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

Semi-synthetic opioid may improve withdrawal symptoms in infants

Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.

7 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

New video PSA may help raise donation for brain research

In its continuing fight to end brain disorders, the American Academy of Neurology Foundation is turning entries submitted to the 2010 Neuro Film Festival into its latest video public service announcement about the need for donations for more research into curing brain disorders.

7 Oct 2010

Cincinnati Children's Hospital receives $12 million grant to create IBD registry

Building on the success of previous efforts among researchers and caregivers to improve the care of chronically ill children, a $12-million grant to Cincinnati Children's Hospital Medical Center will allow creation of a registry system unlike any before it, providing information in real time on thousands of cases around the country – and eventually the world.

7 Oct 2010

Congress scientific program to highlight new developments in Parkinson's disease

The 7th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson's Disease (MDPD 2010), to be held in Barcelona, December 9 - 12, 2010, aims to provide specialists with the latest developments in the understanding of cognitive and psychiatric aspects of the disease.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec today announced that more than 45 company and partner-sponsored platform and poster presentations will be presented during the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, October 13 - 16, 2010.

6 Oct 2010

iMDsoft to install MetaVision clinical information system across Queensland's network of public hospitals

iMDsoft® announced today that the Government of Queensland has signed an agreement to install MetaVision® in selected ICUs across the state's network of public hospitals. MetaVision will be installed in 14 hospitals and will be implemented in a diverse range of ICU settings including pediatric, neurology and cardiac units. The university-affiliated Gold Coast Hospital will be the first to implement MetaVision under this agreement.

6 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

New biomarker could aid in accurate diagnosis of Alzheimer's disease

A set of proteins found in blood serum shows promise as a sensitive and accurate way to diagnose Alzheimer's disease, researchers at UT Southwestern Medical Center have found as part of a statewide study.

6 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

Archimedes publishes FPNS clinical study results in Pain journal

Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

5 Oct 2010

Researchers endeavor to create map of human brain's wiring using MEG technology

As a part of a $30 million dollar National Institutes of Health (NIH) initiative to map the human brain, Saint Louis University neurosurgeon Richard Bucholz, M.D. will image the brains of healthy adults with MEG technology, providing key information about brain function.

5 Oct 2010

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Thirteen national and international experts in the field of Brain Stimulation in Psychiatry and Neurology will meet October 7 and 8 during a conference held at the Douglas Mental Health University Institute. They will present research findings and ground-breaking clinical applications concerning the use of brain stimulation techniques. New treatments still under development, such as transcranial magnetic stimulation, will also be discussed. Close to 150 participants are expected to take part in this conference.

5 Oct 2010

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

New research shows how old people are when they first develop Parkinson's disease is one of many clues in how long they'll survive with the disease. The research is published in the October 5, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010